Drug recall · July 5, 2017
Blephamide recall
Why: Failed Impurities/Degradation Specifications: stability testing results did not meet the specification for impurities.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Blephamide (sulfacetamide sodium and prednisolone acetate ophthalmic ointment, USP) 10%/0.2% sterile, 3.5 g tube, RX only, Manufactured by Allergan, Irvine, California, 92612, U.S.A., NDC: 0023-0313-04.
- Lots / codes
Lot: 93802, EXP NOV 2019
- Quantity
- 648 units
- Company
- Allergan Sales, LLC, Waco, TX
- Distribution
- Nationwide in the US
- Initiated
- May 1, 2017 · Voluntary: Firm initiated
- Classified
- June 29, 2017
- Reported
- July 5, 2017
- Ended
- May 1, 2019
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Prednisolone
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.